Tamsulosin Hydrochloride Capsule
Product Images NDC 62135-775

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 62135-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Chartwell Rx, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tamsulosin-30s-container-1 (Tamsulosin HCl Capsules 90s Label)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by Chartwell RX, LLC, NDC 62135-775. The label includes dosage form and strength, manufacturer details, storage instructions, and a barcode. It notes a package size of 90 capsules and mentions patient information availability online at chartwellpharma.com.*

FDA Label Image

Tamsulosin-figure1 (Tamsulosin HCl Capsules Figure1)

A line graph comparing plasma concentration (ng/mL) of Tamsulosin Hydrochloride over time (hours) under fasted and fed conditions. The graph shows higher peak concentration reached earlier when fasted versus a lower, delayed peak when fed, with both curves declining over 36 hours.*

FDA Label Image

Tamsu-fi2a (Tamsulosin HCl Capsules Figure2a)

A line graph depicting mean change over duration of treatment (weeks) for three groups: 0.8 mg treatment, 0.4 mg treatment, and placebo. The x-axis shows treatment duration from baseline to 13 weeks, while the y-axis shows mean change values ranging from 0 to -10. Data points and error bars illustrate decreasing mean change over time, with both treatment groups showing greater mean reductions compared to placebo.*

FDA Label Image

Tamsu-fig2b (Tamsulosin HCl Capsules Figure2b)

A line graph depicting mean change over treatment duration in weeks for three groups: 0.8 mg dose, 0.4 mg dose, and placebo. The x-axis shows weeks of treatment up to 13, and the y-axis shows mean change values with data points for each treatment group. The chart includes sample sizes at various time points and distinguishes treatment groups by different markers and line styles.*

FDA Label Image

Tamsu-fig3a (Tamsulosin HCl Capsules Figure3a)

Line graph depicting mean change in urinary flow rate (mL/sec) over treatment duration in weeks for Tamsulosin Hydrochloride 0.8 mg, 0.4 mg, and placebo groups. The x-axis shows duration in weeks, and the y-axis shows mean change in flow rate. The graph compares treatment effects over time including a last observation carried forward (LOCF) data point.*

FDA Label Image

Tamsu-fig3b (Tamsulosin HCl Capsules Figure3b)

A line graph depicting mean change in mL/sec over duration of treatment in weeks for three groups: 0.8 mg, 0.4 mg, and placebo. The x-axis shows treatment duration from 0 to 13 weeks, and the y-axis shows mean change from 0 to 3 mL/sec. Different symbols represent the treatment groups as indicated in the legend.*

FDA Label Image

Tamsulosin-structure (Tamsulosin HCl Capsules Structure)

Chemical structure of Tamsulosin Hydrochloride, showing the molecular arrangement including the sulfonamide and methoxy functional groups along with the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.